Drug Delivery FDA Approval Life Science 
pharmaphorum
NOVEMBER 4, 2020
Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the money into European therapeutics and medical device companies. The third fund is now closed.
XTalks
NOVEMBER 5, 2024
Additionally, a collaboration with NurExone is creating an intranasal delivery system for exosome-based therapies targeting spinal cord injuries, with potential expansion into other neurological uses. Polyrizon’s focus on intranasal protection aligns with a rapidly expanding market in drug delivery innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JANUARY 18, 2023
Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. The inhaler is approved as a rescue medication for adults with asthma to help treat bronchoconstriction and asthma attacks.
XTalks
NOVEMBER 4, 2021
Related: Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer. The FDA approval of Vuity exemplifies our continued pursuit of innovative new treatments that push the boundaries of what’s possible in eye care.”. Vuity is available by prescription.
XTalks
JULY 26, 2024
These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.
XTalks
MARCH 21, 2025
The rankings are based on each companys ability to tackle critical challenges from drug delivery and diagnostics to personalized therapies using cutting-edge science. With a 30-month shelf life and rapid absorption, Neffy offers an on-the-go alternative to auto-injectors. Here are 20 companies leading the way in 2025.
XTalks
NOVEMBER 3, 2021
The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Read the full articles here: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11.
Expert insights. Personalized for you.
96 
Let's personalize your content